Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Karus Therapeutics Announces Collaboration with Babraham Institute

Published: Tuesday, December 18, 2012
Last Updated: Monday, December 17, 2012
Bookmark and Share
Collaboration to explore PI3 kinase inhibitors in the treatment of inflammatory diseases.

Karus Therapeutics has announced that it has entered into a collaboration with the Babraham Institute (Cambridge, UK), to further characterize novel treatments for inflammatory diseases through the regulation of phosphatidylinositol-3-kinase (PI3K) - a family of enzymes important to immune cell function.

This collaboration will be led by Dr Stephen Shuttleworth, Chief Scientific Officer of Karus.

He will be working closely with the Babraham team headed by Dr Len Stephens and Dr Phillip Hawkins to further investigate PI3K signaling and the immune response and, in particular, the role of the different isoforms of the PI3K catalytic subunit p110 on neutrophil cell function.

Under the terms of the agreement, the team will further interrogate the mechanism by which Karus Therapeutics’ PI3K-p110 beta and PI3K-p110 delta inhibitors impact on neutrophil function and immune responses, with the aim of developing more effective treatments for inflammatory diseases such as rheumatoid arthritis. Financial terms were not disclosed.

Dr Shuttleworth said: “Dr Stephens and Dr Hawkins are key opinion leaders in the area of PI3K biology, notably in the context of neutrophil function. They have recently made key discoveries that are having a significant impact on the design of isoform-selective PI3K inhibitors for the treatment of chronic immune disorders. I have successfully collaborated with the Babraham team in the past and am delighted to be working with them again at Karus.”

Dr Hawkins added, “We have already shown in vivo that targeting of PI3K-p110 beta and PI3K-p110 delta is an effective way to treat rheumatoid arthritis in small animal models. By working with Karus, we gain unique access to scientific leadership in the field of PI3K inhibitor design and development. We look forward to working with Stephen and his team to convert scientific discovery into medical breakthrough.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More Than 4,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Karus Therapeutics Appoints Penelope Ward as CMO
Dr Ward will drive Company’s HDAC6 and PI3K inhibitor programmes.
Tuesday, November 12, 2013
Karus Therapeutics Appoints Scientific Advisory Board
Company announces move to new Oxford facilities.
Tuesday, April 09, 2013
Karus Secures Series B Financing from a Syndicate of Leading VC Investors
New investment to support the development of Karus’s innovative PI3K and HDAC6 programmes through early human trials.
Thursday, January 17, 2013
Karus Commences Preclinical Development of Novel Immune and Inflammation Programmes
The Company aims to initiate clinical trials for both programmes in 2011.
Wednesday, November 03, 2010
Scientific News
Platelets are the Pathfinders for Leukocyte Extravasation During Inflammation
Findings from the study could help in the prevention and treatment of inflammatory pathologies.
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Benchtop Automation Trends
Gain a better understanding of current interest in and future deployment of benchtop automated systems.
Some Women With PCOS May Have Adrenal Disorder
Researchers at NIH have found that a subgroup of women with PCOS, a leading cause of infertility, may produce excess adrenal hormones.
Alzheimer's Genetics Point To New Research Direction
A University of Adelaide analysis of genetic mutations which cause early-onset Alzheimer’s disease suggests a new focus for research into the causes of the disease.
Penn State, TB Alliance, and GSK Partner To Discover New Treatments For TB
A new collaboration between TB Alliance, GSK, and scientists in the Eberly College of Science seeks to find new small molecules that can be used to create antibiotics in the fight against tuberculosis (TB).
Manufactured Stem Cells To Advance Clinical Research
Clinical-grade cell line will enable development of new therapies and accelerate early-stage clinical research.
Faster Detection of Pathogens in the Lungs
Thanks to new molecular-based methods, mycobacterial pathogens that cause pulmonary infections or tuberculosis can now be detected much more quickly.
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Contagious Cancers Are Spreading in Shellfish
Direct transmission of cancer among some marine animals may be more common than once thought, suggests a new study published in Nature by researchers at Columbia University Medical Center (CUMC).
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!